Atopic Dermatitis

In this video interview, Andrew Blauvelt, MD, MBA, dives into the current state of atopic dermatitis treatment from his talk presented at the Annual Society of Dermatology Nurse Practitioners Symposium, held April 22-23, in Nashville, Tennessee.

At the opening session of the Society of Dermatology Nurse Practitioners Annual Symposium, Kathleen Haycraft, DNP, FNP-BC, DCNP, FAANP, delved into the revolutionary and evolutionary advances shaping dermatology in 2022.

In her presentation at the 3rd Annual Society of Dermatology Nurse Practitioners Symposium, Lisa Swanson, MD, discussed the important updates in pediatric dermatology, including early life interventions, food allergies, and more.

Unlike other psychological comorbidities, sexual dysfunction is a little explored field within AD.

Jonathan Silverberg, MD, the associate professor of dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC, joins us to discuss a poster from the December 2021 RAD conference.

Andrew Blauvelt, MD, MBA, shares clinical pearls for the management of atopic dermatitis with systemic therapy.

An expert dermatologist provides insight on unmet needs in clinical trial endpoint measurements that would improve the management of atopic dermatitis.

Dr Andrew Blauvelt discusses the relevance of dupilumab treatment response as seen in the LIBERTY AD OLE and LIBERTY AD CHRONOS studies and shares his approaches to improving atopic dermatitis management.

Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, talks about how education of patients is so important, the upcoming parts of the AAD guidelines to look forward to, and more.

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research expands on her talk from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is held from April 9 to 11 in Baltimore, Maryland.

Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, discusses the American Academy of Dermatology's approach to atopic dermatitis management.

What role will digital therapeutic agents have in the coming years of atopic dermatitis treatment? It’s still being studied, but Jonathan Silverberg, MD, reviewed an interventional study that may provide key insights into what’s to come.

Lawrence Eichenfield, MD, of Rady Children's Hospital-San Diego, California, discusses the importance of recognizing children with more severe atopic disease and a team approach to treatment.

Brett King, MD, of Yale School of Medicine, discusses the future of atopic dermatitis treatment.

A RAD conference abstract presentation highlights the demographic, prevalence, and comorbidity data for adults with atopic dermatitis.

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research, explores the hidden burdens of itch that many pediatric patients and parents have to deal with on a daily basis. She expanded on her talk from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference was held from April 9 to 11 in Baltimore, Maryland

In her talk at the Revolutionizing Atopic Dermatitis Conference, Madison Cook, BS, gives tips on how to increase accountability, common barriers to overcome with patients, and more.

What do topical PDE4 inhibitors bring to the treatment toolbox? Which patients are likely to get the most use out of them? Robert Sidbury, MD, MPH, answers these questions and more in this video interview.

An abstract presented at the Revolutionizing Atopic Dermatitis conference discussed the impact of treatment with dupilumab on quality of life for children aged 6 months to 5 years with atopic dermatitis, as well as their caregivers.

Experts take a closer look at when to watch, and what to watch for in patients on JAK inhibitors.

Korey Capozza, MPH, the founder and executive director of Global Parents for Eczema Research dives into the importance of the results from their recently released study.

Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, expands on his AD overview from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is being held from April 9 to 11 in Baltimore, Maryland.

The Revolutionizing Atopic Dermatitis conference begins with presentations focused on new treatments, data, and more in atopic dermatitis.

Andrew Blauvelt, MD, MBA, reviews clinical implications from the phase 3 LIBERTY AD CHRONOS study examining the efficacy of dupilumab plus topical corticosteroids in adult patients with moderate to severe atopic dermatitis.

An expert dermatologist provides key takeaways and the real-world significance of dupilumab use for the treatment of atopic dermatitis.